Alerus Financial Corporation enters September with a modest but notable signal: a director making an open-market purchase the same week the stock slipped nearly 1.4%.
The most interesting data point this week is in the insider register. Director Jeffrey Bolton bought 1,000 shares at $32.45 on September 1 — a discretionary open-market purchase, not a grant or award, and not made under a 10b5-1 plan. The trade is small in dollar terms ($32,450), but it carries more signal than a scheduled transaction. Bolton was also among the directors who received stock awards in May 2025, so this is an additional, voluntary commitment at current prices. Net insider activity over the past 90 days registers a net 1,000 shares bought — thin numerically, but directionally positive at a time when the stock has lost roughly 2% over the past month.
The lending market tells a quiet story. Short interest is running at 4.8% of the free float — meaningful, but not extreme — and edged up about 2.1% on the week after drifting lower through most of August. Cost to borrow has eased 10% over the week to around 0.48%, its lowest level in six weeks. Availability is wide open: over 580% of short interest is covered by available shares, well above the 52-week floor of 419%. That looseness removes any squeeze dynamic from the picture. The ORTEX short score slipped to 48.4 from 50.5 on Monday — a mild softening, consistent with the overall picture of a position that is neither crowding nor unwinding aggressively.
Options positioning adds a modest defensive tilt. The put/call ratio is running at 0.10, above the 20-day average of 0.07 by about 1.3 standard deviations. That is elevated relative to recent norms but still very low in absolute terms — the 52-week range runs all the way up to 1.51. This is a lightly traded options market, so the z-score deserves context: the ratio shifted sharply around August 21 from 0.06 to 0.10, and has held that level since, suggesting some incremental demand for downside protection rather than a meaningful repositioning.
On the Street, the analyst backdrop has been constructive. Following Q2 results at the end of July, both Piper Sandler and Keefe Bruyette & Woods raised price targets — to $37 and $32 respectively — while holding neutral ratings. Raymond James reinstated coverage in early July with an Outperform and a $34 target. The consensus target of $35.40 sits about 9% above the current price of $32.61. The bull case centres on loan growth, improving net interest margins, and fee income diversification through wealth management. Bears point to softer loan originations in construction and consumer segments in early 2026. Valuation is undemanding: the stock trades at 11.5x trailing earnings and 1.3x book, both stable over the past month. The forward EPS growth factor ranks in the 84th percentile — the strongest factor score in the snapshot — while near-term EPS momentum (24th percentile on 30 days) remains a weak spot.
One institutional move worth noting: Goldman Sachs Asset Management added 386,798 shares as of July 30, bringing its position to 432,647 shares. That is a material build for a relatively thinly traded community bank name. Endeavour Capital, meanwhile, trimmed 222,711 shares in the quarter, partially offsetting the Goldman inflow. There are no 13D activist filers on the register; the activist table shows only passive 13G holders, and the Vanguard Group's 13G/A filed in March 2026 showed zero shares remaining — a full exit from the position. Stakes are as last disclosed, and holders dropping below 5% may not file again.
The next earnings event is scheduled for October 28. The last three results produced quiet positive moves of roughly 1–1.3% on the day, suggesting a market that digests these prints without drama. With the borrow market loose, short interest contained, and the Street cautiously constructive, what to watch ahead of that date is whether loan growth and NIM data in the interim — and the Goldman stake build — attract further institutional attention.
See the live data behind this article on ORTEX.
Open ALRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
